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Abstract—The Hemolytic Disease of the Fetus and Newborn
(HDFN), if untreated, can have severe consequences on baby’s
health, eventually causing death. Prevention and diagnosis of
pregnancies at risk of HDFN consists in quantitative analysis in
hospital every 2-4 weeks of blood group antibodies in maternal
serum. The most important antibodies to be monitored are anti-
Rhesus D (or anti-RhD) ones. Nowadays several portable systems
for different healthcare applications have been developed towards
decentralization of diagnosis thanks to the enormous advances in
electrochemical biosensing. Home-monitoring of pregnancies at
risk of HDFN could significantly improve patients’ life quality.
Here we demonstrate for the first time label-free quantitative
detection of anti-RhD antibodies by means of electrochemical
impedance spectroscopy (EIS), suitable for integration within a
complete portable device. The specificity of the sensor was also
proved.
Index terms— Hemolytic disease of the fetus and newborn,
HDFN, Rh disease, electrochemical sensors, electrochemical
impedance spectroscopy, blood typing
I. INTRODUCTION
The Hemolytic Disease of the Fetus and Newborn (HDFN)
is a condition that, if untreated, can have severe consequences
on the fetus/neonate health: 1 over 4 cases result in intense
anemia and irreversible damages to the nervous systems (ker-
nicterus); another 25 % of the cases in abnormal accumulation
of fluid in 2 or more fetal compartments (hydrops foetalis) and
eventually death [1]. Prevention and diagnosis include frequent
analysis of maternal antibodies in serum [2]. In this regard, the
realization of a portable device for monitoring of the immune
response of the patient represents a significant step towards
decentralization of medical care.
The HDFN can occur in the presence of a mismatch between
the blood group of the mother and the fetus. Blood is generally
classified according to the so-called ABO system into four
different groups (A, B, AB, 0), depending on the presence
or absence of the A and B antigens on the surface of the
Red Blood Cells (RBCs, also called erythrocytes). Another
important system that must be considered in blood typing
is the Rhesus or Rh system [3]. So far, several different Rh
antigens have been identified. However, the Rhesus D antigen
is the most important one in terms of clinical relevance. If
this antigen is present on the erythrocytes of the individual,
his blood group is called Rh positive (Rh+), otherwise it is
defined Rh negative (Rh-). A summary of the characteristics
of the ABO and RhD systems is given in Figure 1. It can be
observed that the absence of a particular antigen implies the
presence in blood serum of the corresponding antibodies that
will cause agglutination in case of contact with incompatible
RBCs. However, no anti-RhD antibodies are present in Rh-
individuals serum until exposure to RhD antigens occurs. This
process of antibodies production in response to alloantigens is
called alloimmunization [4]. The HDFN can be associated to
different blood systems and subsystems. The most critical one
Fig. 1. Chart of different blood groups showing the types of antigens present
on each kind of red blood cell and the antibodies present in the corresponding
serum.
Fig. 2. Origin and development of the HDFN: a) the Rh- mother during
pregnancy comes in contact with the blood of her Rh+ fetus; b) the mother
will produce anti-RhD antibodies in response to fetal RhD antigens (alloim-
munization); c) alloantibodies cross the placenta and attack fetal RBCs with
severe consequences on fetus health.
is related to the RhD antigen occurring when the mother is
Rh- and the fetus Rh+ [5]. This is normally referred to as ”Rh
disease” [2].
The origin and development of the HDFN is explained in
more detail in Figure 2. When an Rh- mother come into
contact with the nonself RhD antigens (typically via previous
pregnancies as in the Figure or via transfusions), anti-RhD
antibodies develop in woman blood serum. If able to cross the
placenta, these antibodies attack the RBCs of the fetus causing
anemia, hepatosplenomegaly (i.e. liver and spleen swelling),
jaundice, permanent damages of the nervous system due to
excess of bilirubin and eventually death [1].
Nowadays, HDFN due to Rhesus D alloimmunization at-
tacks 0.4 over 1000 pregnant women and still represents the
main cause of fetal anemia [1]. Screening programs to deter-
mine high-risk situations consists in monitoring the possible
sensitization of the mother by analyzing her serum antibodies
during pregnancy by means of the indirect Coombs test, also
called Indirect Antiglobulin Test (IAT) [2]. This laboratory
procedure exploits agglutination to reveal the presence in
mother’s serum of IgG alloantibodies that are likely to cross
the placenta. In case of positive result, monthly checkups
to quantitatively analyze maternal alloantibodies are required
until the 18th week of gestation. Afterwards, the monitoring
frequency should be doubled [1]. The amount of alloantibodies
is typically determined by titration. The antibody titre is
defined as the inverse of the maximum dilution factor at
which it still possible to detect the antibodies in serum. If
their amount increases significantly over time, it is possible
to conclude that fetal RBCs are causing an immune response
in mother’s serum [1]. In this case, intrauterine or exchange
transfusions in the newborn period can be necessary [5].
IATs tests oblige pregnant women at risk of HDFN to have
frequent checkups in hospitals [1]. The development of a Lab-
On-a-Chip (LOC) device able to send relevant data to doctors’
device will certainly improve patients’ life by allowing health
monitoring at home. In this respect, electrochemical sensors
represent a promising class of devices to realize portable and
low cost diagnostic systems thanks to their easy miniaturiza-
tion, small sample volume and easy integration into micro-
fabrication processes for mass production [6]. In particular,
EIS is a powerful electrochemical technique for detection of
surface phenomena or of variations in bulk properties [7]. It
is based on the analysis of the electrical impedance of the
system, that is then properly fitted by means of an appropriate
equivalent circuit to obtain quantitative information about
circuit parameters [8]. The great potential of this method
for biosensing applications is represented by the possibility
of label-free detection, thus avoiding the need to modify the
biomolecules with enzymes or fluorescent labels [9].
Physical adsorption of bioprobes on the electrodes surface
offers a very convenient method for electrodes surface modifi-
cation thanks to the minimum alteration of the biomolecules.
Consequently, the risk of detection capabilities degradation
is reduced. Moreover, they do not require several time-
consuming steps, thus simplifying significantly the experimen-
tal protocol for the fabrication of the biosensor [10].
In the present paper, we propose the new idea of a portable
electrochemical sensor for quantitative analysis of alloantibod-
ies in mother’s serum for monitoring pregnancies at high risk
of HDFN. RhD peptides were physically adsorbed on the gold
electrodes surface in order to form a probe layer for sensing of
anti-RhD antibodies. Our preliminary results demonstrate the
quantitative label-free detection of Rhesus D alloantibodies by
means of electrochemical impedance spectroscopy (EIS).
II. EXPERIMENTAL
A. Materials
Dual Screen Printed Gold Electrodes (SPGEs) were pur-
chased from Dropsens (Spain). Rabbit polyclonal IgG anti-
RhD antibodies, rabbit polyclonal IgG isotope controls and
Rhd peptides were purchased from Abcam (UK). All other
chemicals were from Merck (Germany) and Sigma-Aldrich
(US). 0.01 M Phosphate buffer saline (PBS, Sigma Aldrich,
P4417) solution at pH 7.4 was prepared using ultrapure water.
B. Peptide immobilization and antibody incubation protocols
Electrochemical cleaning of all SPGEs was performed in a
0.5 M H2SO4 aqueous solution by multiple cyclic voltamme-
try scans between -0.2 and +1.5 V at a scan/rate of 50 mV/s
until complete overlapping of two subsequent voltammetric
curves [11]. The RhD peptides were physically adsorbed on
the electrodes by incubation overnight at 4◦C at dark. This step
was followed by accurate washing in PBS to remove unbound
peptides. The antibodies were incubated overnight at 4◦C at
dark with anti-RhD antibody solutions in PBS. A final rinsing
step was performed to remove unbound antibodies residues.
C. Morphological and electrochemical measurements
All EIS measurements were performed using an Autolab
potentiostat (Metrohm, Switzerland) controlled by a Nova
1.11 software (Metrohm, Switzerland). A sinusoidal AC signal
with an amplitude of 10 mV was applied to the sample
with a frequency range from 0.1 to 105 Hz. MEISP software
by Khumo Chemical Laboratories was used for impedance
fitting. This is based on complex non linear least-square fitting
algorithm LEVM/LEVMW [12]. The software generates also
values representing the accuracy of the fitting. In order to
ensure a good fit, the χ2 was always brought to values smaller
than 10−3 and the standard deviation of each parameter to less
than 5%.
III. EXPERIMENTAL RESULTS AND DISCUSSION
The peptide concentration used for sensor surface modifi-
cation was optimized to achieve the highest surface coverage.
The presence of immobilized peptides onto the surface was
detected by means of EIS measurements. The impedance
response of electrochemical systems can be fitted by means of
the Randles equivalent circuit (inset of Figure 3) [13]. With
respect to the usual Randles model, here the normal capacitor
was replaced by a constant phase element (CPE) to account
for deviations from ideal behaviour typical of double layer
capacitors. [14]. The Rct value can be used to detect surface
modifications since these are expected to have a significant
effect on the electron transfer capabilities at the electrode
interface [14]. It is important to notice that, in order to
normalize the effect due to possible surface differences among
distinct SPGs, in the present paper a percentage variation
of Rct, ∆Rct%, with respect to the immediately preceding
functionalization step is used instead of an absolute one,
according to the following equation:
∆Rct% =
Rct,B −Rct,A
Rct,A
∗ 100, (1)
where Rct,A and Rct,B are the charge transfer resistances after
the functionalization steps A and B, respectively. An example
of a typical electrochemical impedance response of a SPGE
is given in Figure 3.
The results of the EIS measurements at different peptide
concentrations are reported in Figure 4. The percentage in-
crement ∆Rct% is calculated versus the bare gold electrode
using equation (1). It is possible to observe that, as expected,
the physical adsorption of the peptides onto the surface causes
an increase in the Rct value of the electrode. However,
the ∆Rct% gain after incubation with the peptides falls
significantly when their concentration is reduced below 500
µg/ml. For this reason, this value was chosen for validation
and calibration of the impedance sensor in order to reduce
peptide consumption, while still maintaining optimum surface
coverage of the probe molecules.
The feasibility of antigen-antibody binding detection and
the specificity of the sensor were also examined by means of
EIS measurements. The results are summarized in Figure 5,
in which the ∆Rct% values after different surface modifica-
tion steps are reported. As explained before, the percentage
variation is always normalized with respect to the previous
Fig. 3. An example of a typical electrochemical impedance response of a
screen printed gold electrode. The fitting was performed by using a modified
Randles equivalent circuit.
functionalization stage using equation (1). Consequently, each
column in Figure 5 must be read separately and cannot be used
for comparisons. The first column shows that the percentage
increment of the Rct value after peptide immobilization with
respect to the bare electrode is about 36%, thus proving the
effective modification of the surface. A further 37% increase
in Rct is achieved versus the peptide-modified electrode when
the sensor are incubated with anti-RhD antibodies at 200
µg/ml, as evident from the second column. A relatively high
concentration was used to facilitate the investigation of the
feasibility of antigen-antibody detection. In the third column
the ∆Rct% after exposure to the isotope control, that is a non-
Fig. 4. The effect of peptide concentration on ∆Rct% values normalized
with respect to the Rct values of the bare gold electrodes. This trend is a
result of reduced coverage when the peptide concentration is reduced. The
error bars refer to the standard deviation among different electrodes.
Fig. 5. The ∆Rct% values after different surface modification steps. It is
important to notice that all percentage increments are normalized with respect
to the previous functionalization step. The error bars refer to the standard
deviation among different electrodes.
Fig. 6. Calibration curve of the impedimetric sensor. The points reported in
the Figure are obtained by means of one-shot measurements. All ∆Rct% are
calculated with respect to the peptide-modified electrodes.The error bars refer
to the standard deviation among different electrodes.
specific antibody, is given versus the peptide-modified surface.
A relatively high isotope concentration was used (250 µg/ml)
as in the case of the specific anti-RhD antibodies. The small
percentage increase in Rct (around 5.7%) proves the specificity
of the sensor. Finally, the last column shows that the ∆Rct%
due to the incubation of the bare gold electrodes with anti-
RhD antibodies at 250 µg/ml is around 8.54%. This modest
value proves that the effect of aspecific absorption of anti-RhD
antibodies on gold is minimum.
The sensors were exposed to different antibody concen-
trations in order to obtain a calibration curve (Fig. 6). The
points reported in the Figure are obtained by means of one-
shot measurements. All ∆Rct% are calculated with respect to
the peptide-modified electrode according to equation (1).
The antigen-antibody binding is proved by the increase
in ∆Rct%. A higher number of bonds is possible at higher
antibody concentrations, leading to larger ∆Rct% values. The
sensor shows linear behaviour in the range 25-250 µg/ml
with a lower detected concentration of 25 µg/ml. This result
is comparable to the theoretical Limit Of Detection (LOD)
of about 50 µg/ml, that can be computed as three times
the standard deviation of the blank (from the second column
of Figure 4) divided by the sensor sensitivity (slope of the
calibration curve [15]) [16]. These results demonstrate for
the first time the feasibility of the fabrication of electro-
chemical immunosensors for quantitative detection of blood
group antibodies. This system could be easily integrated in
the future with a portable device for decentralized monitoring.
Improvement of sensor performance in terms of sensitivity
[17] and LOD [18] can be obtained by nanostructuring the
electrodes .
In the future other immobilization techniques, like covalent
binding using EDC/NHS chemistry can be investigated and
compared to physical adsorption. Moreover, the same elec-
trochemical sensing principle can be used for blood typing
or for quantitative analysis of other important blood groups
antibodies that are relevant for HDFN.
IV. CONCLUSION
A label-free electrochemical sensor for quantitative de-
tection of anti-RhD antibodies was fabricated for the first
time through the immobilization of RhD peptides on the
surface. This device can represent the first step towards home
monitoring of HDFN in pregnant women. This system would
significantly improve patients’ life. Future work will include
nanostructuring of the electrodes and comparison with other
immobilization techniques to improve sensor perfomance.
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